April 7, 2025

NRG Oncology Broadcast archives are accessible from our website at any time. Please bookmark this link for your convenience.

The NRG Oncology Podcast co-hosts talk with Dr. Clifford Hudis, CEO of ASCO, about ASCO and its impact in the NCTN, action through advocacy, and the cost and complexity of conducting clinical research.

Spotify | Apple Podcasts | YouTube | Amazon Music

TERMINATIONS

BREAST

EAY191-N2: Permanent study closure; memorandum dated April 4, 2025 (posted on CTSU)

NRG-BR004: Permanent study closure; memorandum dated April 4, 2025 (posted on CTSU)

AMENDMENTS

The following protocol amendments, which are in response to an NCI Action Letter, dated March 31, 2025, for CTEP-supported studies that involve atezolizumab, are posted with study-specific instructions on individual study pages on the CTSU website.

• NRG-BN010: Amendment 5; protocol version date: March 13, 2025 (closed to accrual)
• NRG-GI004/SWOG-S1610: Amendment pending. Refer to the March 31, 2025, notice regarding the temporary closed to accrual.
• NRG-GY009: Amendment 15; protocol version date: March 10, 2025 (closed to accrual)
• NRG-LU007: Amendment 5; protocol version date: March 13, 2025
• RTOG 1216: Amendment 12; protocol version date: March 13, 2025

OTHER PROTOCOL NOTICES

1. ALL DISEASE SITES

NRG-GY022: Reminder: Actively Recruiting MALE Patients only Read More

2. BIOSPECIMEN BANKS

Printing Biospecimen Transmittal PDFs from Rave

Please note an effort is underway to clarify how to obtain a Biospecimen Transmittal PDF for submission to the NRG Oncology Biospecimen Bank. Read More

3. BREAST

NSABP B-43, B-47 and B-52: Final Call for Data for Study Termination; memorandum dated April 7, 2025 (posted on CTSU)

4. CANCER CARE DELIVERY RESEARCH

NRG-CC012CD: The Spanish-translated consent form for Amendment 2 and CIRB approval of the form are available on the CTSU website

5. CANCER PREVENTION & CONTROL

NRG-CC005/FORTE: FORTE Fridays eNewsletter

NRG-CC010: The study is open to NRG sites in Japan and South Korea. The optional biospecimen collection does not apply to sites participating in these countries.

6. GYNECOLOGIC

NRG-GY019: Approaching interim efficacy analysis target. To provide the Data Monitoring Committee with the most accurate information, please submit all overdue data and update any outstanding patient data queries by April 20, 2025. 

NRG-GY026: Now accruing patients of all stages and all histologic subtypes of endometrial cancer. 

NRG-GY031: Please note, there is an error in the section 4.2 table and the Biospecimen Collection and Submission Manual. The Part I PK collection is to be done on Cycle 1, Day 1, and Cycle 1, Day 8. This will be updated with the next amendment.

7. HEAD & NECK

NRG-HN008 - Reminder: please update treatment and AE data weekly. This is a Phase I trial and timely data submission is very important. 

8. IROC DIAGNOSTIC IMAGING GUIDANCE

IROC Diagnostic Imaging has posted an instruction and troubleshooting guide for the following NRG studies using TRAIL (TRIAD Rave Automated Imaging Log)

• BN007, BN011, BN012, BN013, BN014
• CC009
• LU007
• GU011, GU012, GU013
• HN014 

These guides are for CRAs and any study team member that submits or gathers images for a study. These slides are now available under the Education and Promotions tab on the CTSU protocol-specific page.

9. VTOC TRAINING

The VTOC Webinar Training Series schedule and registration is available for NRG Oncology Research Associates working on NRG-BN014, NRG-BR009, NRG-CC003, NRG-CC005, NRG-CC011, NRG-CC013, NRG-HN001, NRG-HN002, and NRG-HN014. Space is limited so register now and reserve your seat. The next webinar training is scheduled for April 9, 2025.

1. NRG Oncology Now Accepting Travel Award Applications for NRG2025 in Washington, DC

We are now accepting applications for travel awards for the upcoming NRG Summer Meeting in Washington DC from July 24-26, 2025. NRG Oncology seeks to support robust participation in our semiannual meetings through the provision of travel support. Current priorities for travel awards include young investigators, study chairs and engaged study champions, active committee members, member institution PI’s, and clinical research professionals who are actively engaged with NRG Oncology committees. If you have any questions about the travel award process, please contact meeting-reg@nrgoncology.org.

The types of Travel Awards include:

·        NRG Clinical Research Professional (CRP)

·        NRG Advanced Practice Provider (APP) new!

·        NRG Early Career Investigator

·        Machtay Young Investigator

The travel award application deadline is May 9, 2025 at 11:59pm ET. Awardees will be notified by May 30, 2025. More information can be found on our Travel Awards webpage.

2. Membership Reminders: Please take a moment to review and update your site person rosters!

NRG Oncology Members are required to designate individuals to fill the NRG Oncology Primary Roles. Primary Roles are:

• Check Addressee
• Contact PI
• LAPS PI
• Lead RA
• Co-Lead RA (optional)
• Local Lead RA
• Principal Investigator (A maximum of 3 and the contact PI is counted as 1)

These roles are used to communicate with respect to NRG Oncology studies, initiate and support staff access requests, and other important information. In order for a person to be assigned a Primary Role, he/she must have an active CTEP ID and be listed on the site's NRG Oncology Roster for the specific institution. A completed NRG Primary Role Change Form (located on NRG Oncology website, under Membership) must be submitted to roster@nrgoncology.org for any Primary Role changes.

The Roster Update Management System (RUMS) allows authorized people at clinical sites to manage roster data for secondary roles using a web-based application. Authorized persons can use RUMS to manage person secondary roles, to request the addition or withdrawal of persons to their associated clinical sites, and to request the addition or withdrawal of child sites from their local network. NCORP authorized users should request rostering of NCORP sites, investigators, and research associates via NCORP-SYS. A person must be rostered before any roles may be requested in RUMS. 

Required secondary roles are Local PI, Contract Contact, Fiscal Contact

Please take a moment and review your roster using RUMS or NCORP-SYS as applicable to ensure all of your network personnel are up to date. Contact roster@nrgoncology.org for assistance.

3. REGISTER TODAY: The NRG-GU012 (SAMURAI) Webinar

The NRG-GU012 “SAMURAI” Study Principal Investigators will be hosting a webinar to discuss the trial and accept any questions regarding the study from sites. This webinar will be held on Friday, June 13th from 12:00-1:00pm ET / 9:00-10:00am PT. NRG-GU012 is a Phase II study of stereotactic ablative radiation therapy (SABR) for patients with unresected renal cell carcinoma receiving immunotherapy. Register here.

4. The NRG Oncology Podcast: New Episode Release April 8th

The NRG Oncology Podcast co-hosts talk with Dr. Clifford Hudis, CEO of ASCO, about ASCO and its impact in the NCTN, action through advocacy, and the cost and complexity of conducting clinical research. Tune in on Tuesday, April 8^th!

Spotify | Apple Podcasts | YouTube | Amazon Music

5. RFA for the NRG Early Career Mentorship Subcommittee

Applications DUE APRIL 25, 2025 - Read more and how to apply

Appointment Notification: By May 9, 2025

6. Annual Call for NRG Oncology Administrative Committee & Sarcoma Subcommittee Member Applications

 Applications DUE APRIL 14, 2025 - Read more and how to apply

7. NRG Oncology is seeking candidates for the following:

• Head & Neck Cancer Committee Surgical Vice Chair
• Imaging Committee Chair
• Lung Cancer Committee Chair

 Applications DUE APRIL 7, 2025 - Read more here

8. Health Care Access Committee Symposium

The NRG Oncology Health Care Access Committee (HCA) will be hosting their annual symposium on Wednesday, April 30, 2025; 1:30-3:00pm ET. The focus of this year’s symposium will be “Conquering the Geospatial Divide Challenging Rural Research & Cancer Care Delivery: Real world discussions with rural providers, trialists, and patient caregivers.” Refer to the agenda or the flyer for details. Please register in advance for this webinar. After registering, you will receive an email with the program link. Agenda | Flyer

9. NRG Member Information Form

We are excited to introduce the NRG Member Information Data Collection Initiative that will allow us to create a comprehensive member database, enabling us to better understand and serve our members. Your information will be kept secure and confidential, ensuring that your privacy is always protected. All members are encouraged to complete the form or indicate that they wish to opt out of this data collection initiative. 

Scan the QR code below or click this link to access the form. 

Questions? Read more here

NRG Oncology is pleased to report the scientific articles that appeared during the previous week, as well as abstracts accepted for presentation in this year’s annual meeting of the American Society of Clinical Oncology.

This publications report includes links, when available, to the article, PubMed abstract, or association abstract.

ACCEPTED ABSTRACTS

Bai J, Borges M, Nguyen-Tan P, Rosenthal D, Caudell JJ, Gillison M, Mell LK, Bruner DW, Yeager K, Eldridge R, Thorstad W, Xu MJ, Medek S, Echevarria M, Awan M, Shin DM, Pugh SL, Yom SS. Identifying multi-level social determinants for disparities in survival and patient-reported outcomes in national head and neck cancer trials. ASCO (American Society of Clinical Oncology). 5/30/2025. Poster Presentation.

Braunstein LZ, Mitchell MP, Bandos H, Sikov WM, Khan AJ, Chen PY, Ganz PA, Jagsi R, D P, White JR, Cecchini RS, Kang H, Puhalla SL, Gergelis K, Julian TB, Mamounas EP, Wolmark N. A phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer (HERO): NRG-BR008. ASCO (American Society of Clinical Oncology). 5/30/2025. Abstr TPS1120. Trial-in-progress Poster Presentation.

Gwede CK, Harris J, Machtay M, Le Q, Thorstad W, Nguyen-Tan P, Siu LL, Dorth J, Lee N, Dunlap N, Chan JW, Bar-Ad V, Patel PR, Chakravarti A, Rao S, Shipstone A, Lanning R, Attwood K, Yom SS, Movsas B. Quality of Life in a Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally Advanced Resected Head and Neck Cancer: NRG/RTOG 0920. ASCO (American Society of Clinical Oncology). 5/30/2025. Poster Presentation.

Mamounas EP, Tang G, Puhalla SL, Swain SM, Ganz PA, Henry NL, Cecchini RS, Reid S, Rastogi P, Geyer CE Jr., White J, Clark AS, Haddad TC, Vidal GA, Wolmark N. Phase III Trial Evaluating Addition of Adjuvant Chemotherapy to Ovarian Function Suppression + Endocrine Therapy in Premenopausal Women with pN0-1, HR+/HER2- Breast Cancer and Oncotype Recurrence Score ≤25 (OFSET): NRG-BR009. ASCO (American Society of Clinical Oncology). 5/30/2025. Abstr TPS615. Trial-in-progress Poster Presentation.

Medina S, Tokuyama N, Hammouda K, Pathak T, Mirtti T, Fu P, Gupta S, Lal P, Sandler HM, Correa R, Chafe S, Shah AB, Efstathiou JA, Hoffman K, Straza M, Hallman MA, Jordan RC, Pugh SL, Feng F, Madabhushi A. Computational Pathology Predicts Docetaxel Benefit for High-Risk Localized Prostate Cancer in NRG/RTOG 0521 (NCT00288080) . ASCO (American Society of Clinical Oncology). 5/30/2025. Poster Presentation.

White J, Cecchini RS, Harris EE, Mamounas EP, Stover DG, Ganz PA, Jagsi R, Anderson SJ, Bergom C, Theberge V, El-Tamer M, Zellars RC, Shumway DA, Chen G, Julian TB, Wolmark N. NRG-BR007: A phase III trial evaluating De-escalation of Breast Radiation (DEBRA) following breast-conserving surgery of stage 1, HR+, HER2-, RS ≤18 breast cancer. ASCO (American Society of Clinical Oncology). 5/30/2025. Abstr TPS625. Trial-in-progress Poster Presentation.

PUBLISHED ARTICLES 

Fleming JL, Pugh SL, Chang SM, McElroy JP, Becker AP, Aldape KD, Shih HA, Ashby LS, Hunter GK, Bahary JP, Schultz CJ, Kavanagh BD, Puduvalli VK, Robins HI, Werner-Wasik M, Mehta M, Chakravarti A. Comprehensive Molecular Analysis in NRG Oncology/RTOG 9813: A Phase III Study of Radiation and Temozolomide Versus Radiation and BCNU/CCNU in Anaplastic Astrocytoma. Int J Radiat Oncol Biol Phys. 2025 Mar 29:S0360-3016(25)00284-6. doi: 10.1016/j.ijrobp.2025.03.043. Epub ahead of print. PMID: 40164352. Read more.

Jia X, Rong Y, Wu Q, Cardenas CE, Court LE, Hrinivich WT, Kang H, Kovalchuk N, Whitaker TJ, Xiao Y, Zhang P, Chen Q. NRG Oncology Assessment of Artificial Intelligence for Automatic Treatment Planning in Radiation Therapy Clinical Trials: Present and Future. Int J Radiat Oncol Biol Phys. 2025 Mar 29:S0360-3016(25)00305-0. doi: 10.1016/j.ijrobp.2025.03.045. Epub ahead of print. PMID: 40164355. Read more.

Please note the following upcoming meetings and abstract submission deadlines

UPCOMING MEETINGS

American Association for Cancer Research (AACR); Apr 25-30, 2025; Chicago, IL

American Association for Thoracic Surgery (AATS); May 2-5, 2025; Seattle, WA

American Brachytherapy Society (ABS); Jun 18-21, 2025; Nashville, TN

American College of Radiology (ACR); May 3-7, 2025; Washington, DC

American Head & Neck Society (AHNS); May 14-15, 2025; New Orleans, LA

American Surgical Association (ASA); Apr 24-26, 2025; San Diego, CA

American Society of Breast Surgeons (ASBrS); Apr 30-May 4, 2025; Las Vegas, NV

American Society of Clinical Oncology (ASCO); May 30-Jun 3, 2025; Chicago, IL

American Society of Colon and Rectal Surgeons (ASCRS); May 11-14, 2025; San Diego, CA

Canadian Association of Radiation Oncology (CARO); Sep 10-13, 2025; Calgary, AB

European Society for Radiotherapy and Oncology (ESTRO); May 2-6, 2025; Vienna, Austria

ESMO Gynaecological Cancers; Jun 19-21, 2025; Vienna, Austria

Society for Clinical Trials (SCT); May 18-21, 2025; Vancouver, BC

Western Association of Gynecologic Oncologists (WAGO); Jun 18-21, 2025; Colorado Springs, CO

UPCOMING ABSTRACT SUBMISSION DEADLINES:

AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; Sep 18-21, 2025; Baltimore, MD; Due to publications committee Jun 10, 2025; Submission deadline Jun 24, 2025, 1:00 pm ET

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; Oct 22-26, 2025; Boston, MA; Due to publications committee Jul 7, 2025; Submission deadline Jul 21, 2025, 1:00 pm ET; LBA and Clinical Trials Sep 10, 2025, 1:00 pm ET

American Society for Radiation Oncology (ASTRO); Sep 28-Oct 1, 2025; San Francisco, CA; LBA Jul 10, 2025, 11:59 pm PT

European Society for Medical Oncology (ESMO); Oct 17-21, 2025; Berlin, Germany; Due to publications committee Apr 25, 2025; Submission deadline May 13, 2025, 21:00 CET; LBA Sep 9, 2025, 21:00 CET (placeholder required)

ESMO Breast Cancer; May 14-16, 2025; Munich, Germany; LBA Apr 15, 2025, 21:00 CET (placeholder required)

ESMO Gastrointestinal Cancers; Jul 2-5, 2025; Barcelona, Spain; Submission deadline Apr 8, 2025, 21:00 CET; LBA Jun 5, 2025, 21:00 CET (placeholder required)

International Gynecologic Cancer Society (IGCS); Nov 5-7, 2025; Cape Town, South Africa; Due to publications committee Apr 21, 2025; Submission deadline May 5, 2025, 23:59 SAST; LBA Sep 29, 2025 (placeholder required)

International Society for Quality-of-Life Research (ISOQOL); Oct 22-25, 2025; Milwaukee, WI; Submission deadline Apr 7, 2025

Radiological Society of North America (RSNA); Nov 30-Dec 4, 2025; Chicago, IL; Due to publications committee Apr 23, 2025; Submission deadline May 7, 2025, Noon CT

San Antonio Breast Cancer Symposium (SABCS); Dec 9-12, 2025; San Antonio, TX; Due to publications committee Jun 25, 2025; Submission deadline Jul 9, 2025

Society for Immunotherapy of Cancer (SITC); Nov 5-9, 2025; National Harbor, MD; Due to publications committee Jun 12, 2025; Submission deadline Jun 26, 2025



Society for Neuro-Oncology (SNO); Nov 19-23, 2025; Honolulu, HI; Due to publications committee May 23, 2025; Submission deadline Jun 6, 2025, 11:59 pm ET; LBA Sep 2, 2025, 5:00 pm ET